Loading...
Please wait, while we are loading the content...
Similar Documents
Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia
| Content Provider | Scilit |
|---|---|
| Author | Kumar, P. N. Suresh Anish, P. K. Rajmohan, V. |
| Copyright Year | 2016 |
| Abstract | Objective: The safety and efficacy profile of risperidone and olanzapine were compared in a double-blind trial that used doses widely accepted in clinical practice. Methods: Subjects (n = 71) who met Diagnostic and Statistical Manual of Mental Disorders-IV criteria for schizophrenia were randomly assigned to receive 2–8 mg/day of risperidone (mean modal dose = 5.5 mg/day) or 5–20 mg/day of olanzapine (mean modal dose = 14.4 mg/day) for 1 year. Results: The two study groups were similar at baseline in all aspects. Seventy-four percent of the participants completed the trial, with no between-differences in the proportion of dropouts. Olanzapine group showed significantly greater improvement in negative symptoms in assessments at $3^{rd}$, $6^{th}$, $9^{th}$, and $12^{th}$ months (P = 0.05, 0.00, 0.00, and 0.00, respectively). Clinical global impression of severity (CGI-S) scores were consistently lower in the olanzapine group at $3^{rd}$, $6^{th}$, and $9^{th}$ months (P = 0.01, 0.03, and 0.05, respectively) as measured by positive and negative symptom scale (PANSS). Total scores on PANSS, positive symptoms, general psychopathology, and CGI improvement showed comparable improvement at $3^{rd}$, $6^{th}$, $9^{th}$, and $12^{th}$ months of follow-up (all subjects, including dropouts). Severity of extrapyramidal symptoms was low in both groups, with no between-group differences. Mean change in body weight, fasting blood sugar, and fasting cholesterol was comparable in both groups. Risperidone group had significant hyperprolactinemia after one year (P = 0.03). Conclusions: Both treatments were well-tolerated and efficacious. Greater reductions in severity of the illness and negative symptoms were seen with olanzapine consistently through 1 year. The frequency and severity of extrapyramidal symptoms were negligible and similar in the two treatment groups. Weight gain, hyperlipidemia, and hyperglycemia were comparable in both groups. Risperidone produced significant hyperprolactinemia. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100124/pdf http://www.indianjpsychiatry.org/article.asp?issn=0019-5545;year=2016;volume=58;issue=3;spage=311;epage=316;aulast=Suresh;type=2 |
| Ending Page | 316 |
| Page Count | 6 |
| Starting Page | 311 |
| File Format | XHTML |
| ISSN | 00195545 |
| e-ISSN | 19983794 |
| DOI | 10.4103/0019-5545.192016 |
| Journal | Indian Journal of Psychiatry |
| Issue Number | 3 |
| Volume Number | 58 |
| Language | English |
| Publisher | Medknow |
| Access Restriction | Open |
| Subject Keyword | Clinical Psychology Negative Symptoms Olanzapine Positive Symptoms Risperidone Schizophrenia Indian Journal of Psychiatry, Volume 58, Issue 3 |
| Content Type | Text |
| Resource Type | Article |
| Subject | Psychiatry and Mental Health |
